|
|
Abstract Abstract: To investigate the effects of anlotinib on proliferation and apoptosis of A549 cells based on phosphatidylinositol 3-kinase (PI3K)/serine-threonine protein kinase (AKT) signaling pathway. A549 cells were divided into the control group, the experimental groups with different doses, the anlotinib group, the positive drug group, the inhibitor group and the activator group. The intervention time was 24 hours. The cell viability, cell morphology, the rate of proliferation, apoptosis and related protein expression levels were detected. The results showed that cell viability decreased after treatment with 20 μmol/L anlotinib. Compared with the control group, the cell growth of anlotinib group and positive drug group was inhibited, the cell proliferation rate, cysteinyl aspartate specific proteinase D1 (Cyclin D1) and the expression levels of p-PI3K and p-AKT decreased, and the number of apoptosis cells and the expression of cysteine aspartic protease-3 (Caspase-3) increased. The inhibitor enhanced these changes, while the activator had the opposite trend to the inhibitor. These results of this study indicate that anlotinib can significantly inhibit the proliferation and promote apoptosis of A549 cells, and its mechanism might be related to the inhibition of PI3K/AKT pathway signal transduction. The results of this study further illustrate the potential value of antilung cancer drugs and provide a new theoretical basis for the research and development of anti-lung cancer drugs.
Key words: anlotinib; lung cancer; kinase signaling pathway; proliferation; apoptosis
（Acta Laser Biology Sinica, 2023, 32(4): 360-367）
|
|
|
|
|
|
|
|
